The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Autolus Therapeutics Limited | Common | 05280R100 | 238 | 39,740 | SH | SOLE | 39,740 | 0 | 0 | ||
CytomX Therapeutics, Inc. | Common | 23284F105 | 6,561 | 855,437 | SH | SOLE | 855,437 | 0 | 0 | ||
Epizyme, Inc. | Common | 29428V104 | 36,162 | 2,331,534 | SH | SOLE | 2,331,534 | 0 | 0 | ||
G1 Therapeutics, Inc. | Common | 3621LQ109 | 15,690 | 1,423,794 | SH | SOLE | 1,423,794 | 0 | 0 | ||
Harpoon Therapeutics, Inc. | Common | 41358P106 | 45,144 | 3,898,422 | SH | SOLE | 3,898,422 | 0 | 0 | ||
MEI Pharma, Inc. | Common | 552798202 | 10,063 | 6,250,000 | SH | SOLE | 6,250,000 | 0 | 0 | ||
Sunesis Pharmaceuticals, Inc. | Common | 867328700 | 1,166 | 2,809,912 | SH | SOLE | 2,809,912 | 0 | 0 | ||
TCR2 Therapeutics, Inc. | Common | 87808K106 | 26,091 | 3,370,982 | SH | SOLE | 3,370,982 | 0 | 0 | ||
Turning Point Therapeutics, Inc. | Common | 90041T108 | 13,786 | 308,686 | SH | SOLE | 308,686 | 0 | 0 | ||
YmAbs Therapeutics, Inc. | Common | 984241109 | 8,803 | 337,291 | SH | SOLE | 337,291 | 0 | 0 |